---
Investor Relations
About Awakn
Awakn Life Sciences is a clinical-stage biotechnology company developing therapeutics to treat addiction, with a near-term focus on Alcohol Use Disorder.
We are focused on treating addiction because it is a significant unmet medical need driven by high prevalence rates and high relapse rates.
Awakn Life Sciences Corp. Stock Price (NEO)
Information provided by Stockdio.
Awakn Life Sciences Corp. (AWKN.NE)
Awakn corporate information
Download latest Awakn Corporate Presentation and visit Awakn Financials Info on Sedar.
Awakn Corporate Governance
Download latest Awakn Corporate Governance documents.
Analyst Coverage
FIRM
Stifel
Maxim Group LLC
ANALYST
Andrew Partheniou
Jason McCarthy
News
TORONTO, CANADA, April 17, 2024 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn” or the “Company”) a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a…
TORONTO, CANADA, April 03, 2024 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn” or the “Company”) a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a…
Toronto, Canada – February 12, 2024 – Awakn Life Sciences Corp. (Cboe CA: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn”), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a…
In relation to the recently announced upcoming General Medical Counsel (“GMC”) medical practitioners tribunal into Dr. Ben Sessa. The allegations made against Dr. Sessa relate solely to Dr. Sessa’s private…
Toronto, Canada – February 5, 2024 – Awakn Life Sciences Corp. (Cboe CA: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn”), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a…
Awakn Designates Program AWKN-002 for Alcohol Use Disorders in the US Market Toronto, Canada – January 24, 2024 – Awakn Life Sciences Corp. (Cboe CA: AWKN, OTCQB: AWKNF, FSE: 954)…
Agreement Includes Exclusive Rights for Treatment of Addiction, Anxiety and Eating Disorders Also Includes Access to Phase 1 Data and Patents Filed in US and Key International Markets Toronto, Canada…
Enquiries
Investor relations:
Anthony Tennyson
CEO, Awakn Life Sciences
anthony.tennyson@awaknlifesciences.com
Media enquiries:
Gordo Whittaker,
CMO, Awakn Life Sciences
gordo@awaknlifesciences.com
Sign Up for Newsletter
MAIN OFFICE
Awakn Life Sciences Corp.
301-217 Queen St. W
Toronto, Ontario M5V 0R2
Canada
© 2023 Awakn Life Sciences Corp | Privacy Policy | Disclaimer
